The concurrent occurrence of OAS and ACS syndrome secondary to HZO is rare event, but potentially leading to complete ophthalmoplegia and blindness.
Hyperthyroidism is a rare risk factor for cerebral venous thrombosis (CVT). Optic nerve dysfunction can develop in patients without previous diagnosis of thyroid ophthalmopathy and in the absence of classic signs and symptoms of this clinical entity.
Case Report
A 28-year-old female was referred to the ophthalmology department with progressively worsening sudden diminution of vision OD for 15 days prior to presentation. Visual deterioration was preceded by severe frontal headache accompanied with an episode of vomiting. She was 1-year postpartum at presentation and had history of irregular menstrual cycles with menorrhagia for 7 months. There was no history of oral contraceptive drug intake. At presentation, her blood pressure was 118/80 mm Hg; pulse rate was 80 beats/min, regular with good volume and best-corrected visual acuity (BCVA) was hand movements with inaccurate projection of rays (PR) -OD and 6/18 with accurate PR -OS. Fig. 3d ]. In view of sudden onset diminution of vision, RAPD, severe headache and neuroimaging findings, a working diagnosis of CVT, papilledema, and auto-immune hyperthyroidism was made. Treatment with mannitol [100 ml, intravenous (IV) three times a day (TDS)], oral glycerol [four teaspoonful four times a day (QID)], oral acetazolamide (250 mg QID), enoxaparin 0.6 ml subcutaneously twice a day (BD), oral warfarin 5 mg once a day (OD), oral carbimazole 20 mg TDS, and oral cholecalciferol 60,000 U once a week, was initiated. After 1 week of initiation of this treatment, oral prednisolone in a dose of 40 mg was added and gradually tapered as documented in Table 1 . Table 1 demonstrates the sequential follow-up of the patient on treatment. Repeat MRI of the brain at 12 weeks was normal [ Fig. 3e and f]. BCVA remained 6/9 OD and 6/6 OS at subsequent follow-up, the last being at 15 months after the initial presentation [ Fig. 1] . The optic disc swelling decreased over time [ Fig. 2c and d] .
The free T3 and T4 levels gradually normalized over a period of 1 year, oral carbimazole was stopped after 14 months, oral warfarin continued at 1.5 mg for 8 months and the patient was advised periodic monitoring of her thyroid function tests and coagulation profile under the supervision of an endocrinologist.
Discussion
Acquired hematological, inflammatory, infectious, hormonal, and immunologic causes along with malignancy account for nearly 85% of the cases of CVT where the patient is predisposed to a pro-thrombotic state. [1] About 15% of the cases are idiopathic. [1] Grave's disease and thyroid storm have been noted to have an association with acute CVT, however, definitive cause is not elucidated. [2] Increased levels of fibrinogen, von Willebrand factor (VWF), plasminogen activator inhibitor 1 (PAI-1), coagulation factors IX and X, and free T4 induced increase in factor VIII have been observed in patients with hyperthyroidism along with shorter activated partial thromboplastin time (APTT) that could account for a hypercoagulable state, thus predisposing to CVT. [2] A reduction in fibrinolysis and this hypercoagulable state in hyperthyroid patients is thyroxine dependent. [2] Thyroid swelling can result in mechanical compression of veins in the neck leading to CVT, however, this pathophysiological mechanism did not play significant role in our patient. As this patient was 1-year postpartum, we cannot exclude the possibility that she would be thrombogenic as well besides hyperthyroidism.
Conclusion
Bilateral optic nerve edema may be a presenting initial manifestation of thyroid eye disease. [3] Thyroid eye disease is usually self-limiting and the patients can be observed for signs of recovery. When indicated, steroids, both oral and intravenous are the medications of choice in patients with compromised optic nerve functions due to optic neuropathy. [4] CVT, optic neuropathy with auto-immune hyperthyroidism as seen in this case is unusual.
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